{"id":"NCT00919711","sponsor":"Amgen","briefTitle":"Study to Evaluate the Safety and Efficacy of Denosumab and Actonel速 in Post Menopausal Women Transitioned From Alendronate Therapy","officialTitle":"A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel速 Therapies in Postmenopausal Women Transitioned From Weekly or Daily Alendronate Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09-01","primaryCompletion":"2011-12-21","completion":"2012-03-05","firstPosted":"2009-06-12","resultsPosted":"2012-12-12","lastUpdate":"2020-07-28"},"enrollment":870,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Osteoporosis"],"interventions":[{"type":"DRUG","name":"Actonel速","otherNames":["Risedronate"]},{"type":"DRUG","name":"Denosumab","otherNames":[]}],"arms":[{"label":"Denosumab 60 mg","type":"EXPERIMENTAL"},{"label":"Risedronate 150 mg QM","type":"ACTIVE_COMPARATOR"}],"summary":"A randomized, open label study to assess the safety and effectiveness of Denosumab, administered every 6 months and Actonel 速 (Risedronate), administered monthly in post menopausal women transitioned from weekly or daily Alendronate therapy.","primaryOutcome":{"measure":"Total Hip BMD Percent Change From Baseline at Month 12","timeFrame":"Baseline to month 12","effectByArm":[{"arm":"Risedronate 150 mg QM","deltaMin":0.5,"sd":null},{"arm":"Denosumab 60 mg Q6M","deltaMin":2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"55 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":17},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["24141036","31776637"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":429},"commonTop":[]}}